Global Respiratory Inhalers Market, By Product Type (Dry Powder Inhaler, Metered Dose Inhaler, Soft Mist Inhalers, Nebulizer), Patient (Adults, Pediatric), Technology (Manually Operated Inhaler Devices, Digitally Operated Inhaler Devices), Disease Indication (Asthma, Chronic Obstructive Pulmonary Disease (COPD), Pulmonary Arterial Hypertension, Others), End User (Hospitals, Clinics, Pharmacies, Respiratory Care Center, Other) – Industry Trends and Forecast to 2030.
Respiratory Inhalers Market Analysis and Size
Respiratory inhalers are used to inhale medicines that are essential part of the treatment for chronic lung diseases. There are numerous products that deliver medicine directly to the airways such as dry powder inhalers, metered-dose inhalers (MDIs), nebulizers and soft mist inhalers. The rapidly increasing prevalence respiratory disorder across the world is amongst the significant factors fueling the growth and demand of global respiratory inhalers market. In addition, the increasing demand for treatment options for respiratory disorders and accessibility of well-developed technologies are also contributing to the growth.
Data Bridge Market Research analyses that the global respiratory inhalers market which was USD 32,516.5 million in 2022, is expected to reach USD 42,107.06 million by 2030, and is expected to undergo a CAGR of 5.87% during the forecast period 2023-2030. This indicates that the market value. “Soft Mist Inhalers” dominates the product segment of the global respiratory inhalers market owing to the rising awareness regarding pulmonary diseases as well as increasing healthcare spending are also lifting the growth of the market. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Respiratory Inhalers Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015-2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Product Type (Dry Powder Inhaler, Metered Dose Inhaler, Soft Mist Inhalers, Nebulizer), Patient (Adults, Pediatric), Technology (Manually Operated Inhaler Devices, Digitally Operated Inhaler Devices), Disease Indication (Asthma, Chronic Obstructive Pulmonary Disease (COPD), Pulmonary Arterial Hypertension, Others), End User (Hospitals, Clinics, Pharmacies, Respiratory Care Center, Other)
|
|
Countries Covered
|
U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, UAE, Egypt, Israel, Rest of Middle East and Africa)
|
|
Market Players Covered
|
AstraZeneca (U.K.), Boehringer Ingelheim International GmbH (Germany), CHIESI Farmaceutici S.p.A. (Italy), GlaxoSmithKline plc (U.K.), Propeller Health (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Beximco Pharmaceuticals Ltd. (Bangladesh), 3M (U.S.), Cipla Inc. (India), Koninklijke Philips N.V. (Netherlands), Merck & Co., Inc. (U.S.), Omron Healthcare, Inc. (Japan), Cohero Health, Inc. (U.S.), PARI GmbH (Germany), Glenmark Pharmaceuticals Limited (India), Senzer Ltd (U.K.), Novartis AG (Switzerland), HELTMAN Medikal A.S. (Turkey), Mundipharma International (U.K.)
|
|
Market Opportunities
|
|
Market Definition
Respiratory inhalers are used to inhale medicines that are essential part of the treatment for chronic lung diseases. There are numerous products that deliver medicine directly to the airways such as dry powder inhalers, metered-dose inhalers (MDIs), nebulizers and soft mist inhalers.
Global Respiratory Inhalers Market Dynamics
Drivers
- Increasing Prevalence of Respiratory Diseases
The rising incidence of respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD), and cystic fibrosis is a significant driver for the respiratory inhalers market. The growing global burden of these conditions drives the demand for effective inhalation therapies
- . Technological Advancements in Inhaler Devices
Advances in inhaler technology have led to the development of more efficient and user-friendly inhalation devices. The introduction of digital inhalers, smart inhalers, and breath-actuated inhalers has improved medication delivery and patient adherence, driving market growth.
Opportunities
- Expansion in Emerging Markets
Emerging economies offer significant growth opportunities for the respiratory inhalers market. Improving healthcare infrastructure, rising disposable incomes, and increasing awareness of respiratory diseases present a favorable market landscape for inhaler manufacturers.
- Increasing Focus on Personalized Medicine
The shift towards personalized medicine creates opportunities for tailored respiratory inhaler solutions. Inhalers with customizable dosing, patient-specific treatment plans, and integrated digital technologies can improve patient outcomes and medication adherence.
Restraints/ Challenges
- Stringent Regulatory Requirements:
Regulatory compliance poses challenges for inhaler manufacturers. Strict regulations regarding safety, efficacy, quality control, and device performance increase the time and cost required for product approvals, hindering market growth.
- Pricing Pressure and Reimbursement Issues
Pricing pressures, cost containment efforts by healthcare systems, and reimbursement challenges can affect market growth. The availability of generic inhalers and the need for cost-effective treatment options may impact the profitability of inhaler manufacturers.
This global respiratory inhalers market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the Respiratory Inhalers market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Recent Development
- In September 2022, Beximco Pharmaceuticals launched ONRIVA TRIO BEXICAP which is a dry inhaler capsule. ONRIVA TRIO BEXICAPis indicated as maintainence therapy for asthma
Global Respiratory Inhalers Market Scope
The global respiratory inhalers market is segmented on the basis of product type, patient, technology, disease indication and end user. The growth amongst these segments will help you analyze meager growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.
Product Type
- Dry Powder Inhaler
- Metered Dose Inhaler
- Soft Mist Inhalers
- Nebulizer
Patient
- Adult
- Pediatric
Technology
- Manually Operated Inhaler Devices
- Digitally Operated Inhaler Devices
Disease Indication
- Asthma
- Chronic Obstructive Pulmonary Disease (COPD)
- Pulmonary Arterial Hypertension
- Others
End User
- Hospitals
- Clinics
- Pharmacies
- Respiratory Care Centre
- Other
Global Respiratory Inhalers Market Regional Analysis/Insights
The global respiratory inhalers market is analysed and market size insights and trends are provided by country, product type, patient, technology, disease indication and end user as referenced above.
The countries covered in the Respiratory Inhalers market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America is likely to lead the global respiratory inhalers market. The regional market has been driven by the rising cases of chronic diseases such as cancer and increase in medical expenses in the region. However, the sudden boom in cancer diagnosis and the increasing rate of death is the main factor propelling the growth of the regional market.
Asia-Pacific is expected to witness significant growth during the forecast period of 2023 to 2030 due to due to rise in the demand of health insurance policies in densely populated countries such as India and China.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure Growth Installed base and New Technology Penetration
Global respiratory inhalers market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment’s, installed base of different kind of products for respiratory inhalers market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the global respiratory inhalers market. The data is available for historic period 2015-2020.
Competitive Landscape and Respiratory Inhalers Market Share Analysis
The global respiratory inhalers market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global respiratory inhalers market.
Some of the major players operating in the global respiratory inhalers market are:
- AstraZeneca (U.K.)
- Boehringer Ingelheim International GmbH (Germany)
- CHIESI Farmaceutici S.p.A. (Italy)
- GlaxoSmithKline plc (U.K.)
- Propeller Health (U.S.)
- Teva Pharmaceutical Industries Ltd. (Israel)
- Beximco Pharmaceuticals Ltd. (Bangladesh)
- 3M (U.S.)
- Cipla Inc. (India)
- Koninklijke Philips N.V. (Netherlands)
- Merck & Co., Inc. (U.S.)
- Omron Healthcare, Inc. (Japan)
- Cohero Health, Inc. (U.S.)
- PARI GmbH (Germany)
- Glenmark Pharmaceuticals Limited (India)
- Senzer Ltd (U.K.)
- Novartis AG (Switzerland)
- HELTMAN Medikal A.S. (Turkey)
- Mundipharma International (U.K.)
SKU-